|The NOGGIN nog (Catalog #MBS546127) is a Protein produced from E. Coli and is intended for research purposes only. The product is available for immediate purchase.
The NOGGIN nog product has the following accession number(s) (GI #4885523) (NCBI Accession #NP_005441.1) (Uniprot Accession #Q13253). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful. The amino acid sequence is listed below:
MQHYLHIRPA PSDNLPL VDLIEHPDPI FDPKEKDLNE TLLRSLLGGH YDPGF MATSPPEDRP GGGGGAAGGA EDLAELDQLL RQRPSGAMPS EIKGLEFSEG L AQGKKQRLSK KLRRKLQMWL WSQTFCPYLY AWNDLGSFWP RYVKVGSCF SKRSCSVPEG MVCKPSKSVH LTVLRWRCQR RGGQRCG WTPIQYPIIS ECKCSC.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Our knowledge of the role of proteins in cellular processes is continually evolving. Most proteins, including NOGGIN are typically involved in one or more signaling pathways or biological processes. Professionally manufactured recombinant proteins are increasingly becoming essential and commonplace tools for elucidating new knowledge about the role of proteins in both health and disease.
Molecular Weight Information: Approximately 46.2 kDa, a single glycosylated polypeptide chain containing 235 amino acids.
Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 10mM HAc to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20 degree C. Further dilutions should be made in appropriate buffered solutions. Biological Activity: The ED50 was determined by its ability to inhibit 5.0 ng/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 0.05-0.08 ėg/ml of NOGGIN.
Endotoxin Level: Less than 1EU/mg of rHu NOGGIN as determined by LAL method.
Usage: This material is offered by MyBioSource Inc. for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. Breast Neoplasms, Cardiovascular Diseases, Disease Models, Animal, Inflammation, Liver Diseases, Liver Neoplasms, Liver Neoplasms, Experimental, Neoplasm Metastasis, Neoplasms, Experimental, Nervous System Diseases are some of the diseases may be linked to Recombinant Human NOGGIN (rHu NOGGIN). Blood, Brain, Placenta, Prostate, Spleen, Uterus tissues are correlated with this protein. The following patways have been known to be associated with this gene. NOGGIN also interacts with the following gene(s): BMP2, BMP4, BMP6, BMP7, BMPR1A, BMPR1B, BMPR2, GDF5.